VIA Pharmaceuticals (VIA Pharmaceuticals) Interest Expense : $-3.56 Mil (TTM As of Dec. 2010)

View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. VIA Pharmaceuticals's interest expense for the three months ended in Dec. 2010 was $ -1.58 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2010 was $-3.56 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. VIA Pharmaceuticals's Operating Income for the three months ended in Dec. 2010 was $ -0.89 Mil. VIA Pharmaceuticals's Interest Expense for the three months ended in Dec. 2010 was $ -1.58 Mil. VIA Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

VIA Pharmaceuticals Interest Expense Historical Data

The historical data trend for VIA Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIA Pharmaceuticals Interest Expense Chart

VIA Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Interest Expense

Get a 7-Day Free Trial

-0.01

-7.73

-3.56

VIA Pharmaceuticals Quarterly Data
	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10
Interest Expense	Get a 7-Day Free Trial															-1.43	-0.38	-0.70	-0.90	-1.58

VIA Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.56 Mil.

VIA Pharmaceuticals (GREY:VIAP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

VIA Pharmaceuticals's Interest Expense for the three months ended in Dec. 2010 was $-1.58 Mil. Its Operating Income for the three months ended in Dec. 2010 was $-0.89 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2010 was $0.00 Mil.

VIA Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2010 is calculated as

VIA Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

750 Battery Street, Suite 330, San Francisco, CA, USA, 94111

Website

http://www.baycitycapital.com

VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.

Executives

Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p.	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp	10 percent owner	750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright	officer: V.P. ? Finance, Controller	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen	director, officer: CEO and President	750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson	director	14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub	officer: SVP, Research & Development	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun	officer: Chief Medical Officer	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd	10 percent owner, other: Possible Member of 10% Group	BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-12-2009

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009